Genotyping Market – Global Industry Analysis and Forecast (2024-2030)

Genotyping Market was valued at USD 20.6 Bn in 2023 and is expected to reach USD 58.93 Bn by 2030, at a CAGR of 16.2 % during a forecast period.
Genotyping Market Overview:
Genotyping is the analytical procedure that examines DNA sequences to determine the genetic constitution in the genotypes of living organisms, including humans, plants, animals, and microorganisms. The genotyping market is driven by the technological advancements in genotyping assay products and the decreasing DNA sequencing prices are driving the growth of the market. Emerging markets are expected to offer lucrative growth opportunities for players in the genotyping assay market.

Genotyping market presents opportunities for innovation and growth while facing challenges related to costs, regulations, and ethical considerations. The growing significance of genomics in treatment planning and disease diagnostics and increasing interest in understanding correlation and genetic variations with health outcomes, treatment response, and disease susceptibility are expected to enhance the genotyping industry's growth.

The growing demand for technologically advanced instruments is also expected to drive market growth. The Asia Pacific Genotyping Market is expected to witness the highest growth during the forecast period due to rapid growth in genetic testing and the increasing awareness of early diagnosis. The increasing prevalence of chronic diseases such as diabetes and cancer, increasing government funding, growing adoption of technologically advanced products, increasing presence of major Genotyping Market players, rising advancements in the healthcare infrastructure, and increasing presence of biopharmaceutical and pharmaceutical companies are driving the genotyping industry growth in North America.

To know about the Research Methodology :- Request Free Sample Report
Genotyping Market Dynamics
Growing Importance and Use of Genotyping in Drug Discovery and Development

With the increased availability of investments and government funding for conducting genomics-based research, several CROs and academics have started gene-based research studies to develop innovative disease management strategies with the help of genotyping. The increasing demand for pharmacogenomics is highlighting the potential for growth in genotyping tests. The drug discovery and development genotyping industry has increasingly adopted these tests for assessing drug efficacy and safety and finding new biomarker assays for drug profile assessment, toxicity prediction, risk assessment, dosing determination, treatment decision-making, and drug response evaluation. Thus, the growing importance and use of genotyping in the drug discovery and development process is expected to drive Genotyping Market growth.

Increasing Prevalence of Genetic Disorders is Driving the U.S. Genotyping Market

In addition to the well over 6,000 known genetic disorders, there are now many new genetic ailments being described in the medical literature. Numerous rare genetic illnesses exist that have gotten significantly less attention and could not have been correctly recognized. Both manufactured and natural environments include a multitude of compounds that might be harmful to an individual's DNA. These agents can be viruses, compounds made by bacteria, fungi, or plants; they can also be industrial chemicals, combustion products, alcohol, UV and ionizing radiation, and even oxygen. The growing prevalence of various target diseases such as cancer, and diabetes is among the essential factors intensifying the growth and demand of the genotyping market. As genotyping is majorly used in drug development for genetic disorders and rare diseases, this has carved the way for genotyping industry growth. Due to the prolonged nature of many of these chemicals, humans have evolved defense systems to lessen the harm they do, as well as techniques for mending the harm that cannot be avoided. The U.S. genotyping market is growing due to different factors that are contributing to the increasing number of genetic disorders in the U.S.

For Example,

1. The most frequent chromosomal disorder to be diagnosed in the US is Down syndrome. Approximately 5,700 newborns born in the United States each year are affected by Down syndrome. This indicates that around 1 in 640 newborns are born with Down syndrome.

2. In the U.S., one in 300 persons has hereditary hemochromatosis. Approximately one million persons in the U.S. suffer from type 1 hemochromatosis, one of the most prevalent hereditary illnesses.

Integration of AI Creates Growth Opportunities for the Genotyping Market

In the realm of DNA analysis, artificial intelligence (AI) has quickly become a game-changer, opening up new avenues and improving speed and accuracy in the complex code that makes life. The development of AI computational tools to swiftly and effectively diagnose genetic illnesses in patients and offer the data foundation for precision medicine therapies is accelerated due to the growing quantity and complexity of genomic sequencing data as well as other biological data points. Deep learning techniques have a lot of promise in identifying genomic variations, such as inherited genetic variants, that are correlated with certain traits or illnesses. It has been demonstrated that by automating the identification of genetic diseases, AI-based technologies may greatly reduce expenses and speed up case reviews. Personalized medicine is one of the main fields in which genotyping finds use. AI can examine an individual's genetic composition and forecast how they would react to particular drugs.

Privacy and Ethical Concerns can Restraint the Market’s Growth

There are ethical and privacy concerns associated with genetic data, which can restrict the growth of the genotyping industry. Informed consent, privacy, and secrecy are possible ethical issues. Concerns regarding privacy and confidentiality include violations that might result in stigmatization and discrimination against members of particular racial groups or individuals in the workplace or health insurance industry, as well as whether or not to notify family members of a genetic marker for a disease, particularly in cases where the original participant donor (proband) is unwilling to provide the information in Genotyping Market.

High cost associated with the research and development proficiencies

For the development of various products and new advanced technologies, there is a high cost for the setups and to conduct various associated research, which is further projected to impede the dry skin treatment industry growth in the timeline period. This genotyping industry report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, Genotyping Market share, the impact of domestic and localized Genotyping Market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic industry growth analysis, market size, category industry growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the genotyping industry.
Genotyping Market Segmentation:
By Technology, the technology is segmented into PCR, Capillary Electrophoresis, Microarray, Sequencing, Mass Spectroscopy and other techniques. The Microarray segment is expected to lead the growth of the global SNP genotyping and analysis industry throughout the projected period, attributed to excellent accuracy rates and applications in biomarker discovery and validation, Genome-wide association studies, pharmacogenomics, clinical testing, forensics and breed discrimination. The expanding genetic testing demand, increased R&D spending, increased genotyping testing volumes and the increased usage of software-based services by research laboratories and academic institutions, the software & services segment is expected to grow at a high rate. Bioinformatics enhances the efficacy of sequencing procedures and aids in the avoidance of mistakes that might arise with standard sequencing methods. Agri-genomics, human illnesses, animal livestock, and microorganisms all benefit from these services. Over the projected period, all of the aforementioned reasons are expected to drive market growth. The increasing demand for advanced diagnostic techniques, forensic & research laboratories, and the growing prevalence of diseases like chronic & genetic disorders are the factors, which are driving the growth of the Genotyping Market segment.



By Application, Diagnostics and personalized medicine segment accounted for the highest share of xx% in 2023 owing to the rising adoption of genotyping products for research and the increasing need for the diagnosis of genetic diseases. In addition, strategic collaborations among players are expected to boost genotyping industry growth. For instance, in February 2019, Centogene entered into a strategic partnership with Sarepta Therapeutics, Inc. to diagnose Duchenne muscular dystrophy patients in the MENA region. Pharmacogenomics is expected to witness the fastest CAGR of xx% from 2023 to 2030. Genotyping helps identify patients suitable for a particular drug based on the patient’s genetic make-up. Identifying population subsets that are responsive or non-responsive helps deliver tailor-made treatment to these individuals with different genetic makeup and helps reduce clinical trial attrition. Moreover, Genotyping Market key players play an active role by providing solutions for pharmacogenomics studies. For instance, RT PCR solution by Thermo Fisher Scientific for pharmacogenomic testing includes TaqMan assays and QuantStudio instruments. It also provides a PharmacoScan solution with a PharmacoScan Assay Kit.


Genotyping Market Regional Analysis:
North America dominated the genotyping market in 2023. The increasing prevalence of chronic diseases such as diabetes and cancer, increasing government funding, growing adoption of technologically advanced products, increasing presence of major market players, rising advancements in the healthcare infrastructure, and increasing presence of biopharmaceutical and pharmaceutical companies are expected to drive the genotyping industry growth in North America. Tuberculosis is a common disease in the U.S. and has become a commonly used tool for investigations and detection in the U.S. Genotyping data such as state public health departments to focus interventions on the epidemiologic clusters and many cases identified. As a result of the increasing prevalence of chronic diseases like tuberculosis, the U.S. is the largest country in genotyping and is expected to enhance the growth of the genotyping market in North America.

Europe is expected to grow at a significant rate during the forecast period. The increasing number of, growing government investment, increasing research and development activities, rising technological advancements, and increasing rapid growth of biopharma and pharma companies are anticipated to accelerate the growth of the genotyping market in Europe. Clinical applications have been refined and expanded in Europe. In Germany, blood group genotyping is very common, especially in pregnant women.

For patients with immunohematologic problems and patients with transfusion, genotyping helps to cure these diseases. These are the major factors expected to drive the growth of the genotyping industry. The Asia-Pacific is the fastest-growing region owing to the rapid increased population and rising prevalence of generic disease due to which genotyping market is growing.

Genotyping Market Competitive Landscape:

The competitive landscape of the genotyping industry has also been examined along with the profiles of the key players being Agilent Technologies Inc., Bio-Rad Laboratories Inc., Danaher Corporation, Eurofins Scientific SE, F. Hoffmann-La Roche AG, Illumina Inc., Laboratory Corporation of America Holdings, Qiagen N.V, Standard BioTools Inc. and Thermo Fisher Scientific Inc.

1. In September 2023, Bio-Rad Laboratories launched new thermal cyclers for genotyping, cloning, and sequencing. The new PTC Tempo 384 and PTC Tempo 48/48 provide enhanced usability and superior thermal performance. These new cyclers are the latest additions to the conventional PCR thermal cyclers of the Bio-Rad portfolio.

2. In January 2024, the new Axiom PangenomiX Array was launched by Thermo Fisher Scientific. It is the most ethnically diverse array to date and provides optimal genetic coverage for pharmacogenomic research and population-scale disease studies.

3. In January 2024, in the UK, a new ‘blood matching’ genetic test was launched by the National Health Service. The aim behind this launch was to improve transfusions for patients with inherited blood disorders. This genetic test was in personalized healthcare for patients with thalassemia and sickle cell disorder.

4. In January 2024, BioResource developed a new genotyping program with the Blood Transfusion Genomics Consortium (BGC), an international consortium of partners, using the STRIDES cohort of BioResource volunteers to test the DNA array.

5. In June 2023, in Europe, Zoetis launched the new PCV2 vaccine with two genotypes. It was the new Porcine Circovirus type 2 vaccine that involves two genotypes, offering protection and broader coverage against PCV2 threat. CircoMax has demonstrated protection against PCV2d, PCV2b, and PCV2a.
Genotyping Market Scope: Inquiry Before Buying



Genotyping Market


Report Coverage
Details


Base Year:
2023
Forecast Period:
2024-2030


Historical Data:
2018 to 2023
Market Size in 2023:
US $ 20.6 Bn


Forecast Period 2024 to 2030 CAGR:
16.2 %
Market Size in 2030:
US $ 58.93 Bn.


 Segments Covered:
by Product
PCR
Capillary Electrophoresis
Microarray
Sequencing
Mass Spectrometry
Others


by Type
Instruments
Reagents & Kits
Software & Services


by Application
Pharmacogenomics
Diagnostics And Personalized Medicine
Agricultural Biotechnology
Animal Genetics
Others



Genotyping Market by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Genotyping Market, Key Players
1. Illumina, Inc(USA)
2. Thermo Fisher Scientific Inc. (USA)
3. Qiagen Inc. (Germany)
4. Fluidigm Corporation (USA)
5. Danaher Corporation (USA)
6. Agilent Technologies Inc. (USA)
7. GE Healthcare Inc. (USA)
8. Bio-Rad Laboratories Inc (USA)
9. Pacific Biosciences of California (USA)
10. F. Hoffmann-La Roche Ltd. (Switzerland)
11. Eurofins Scientific Inc. (Luxembourg)

Frequently Asked Questions

1. What is the projected market size & growth rate of the Genotyping Market?
Ans- The Genotyping Market was valued at USD 20.6 billion in 2023 and is projected to reach USD 58.93 billion by 2030, growing at a CAGR of 16.2 % during the forecast period.

2. What is the key driving factor for the growth of the Genotyping Market?
Ans- The increased prevalence of cancer is likely to be a significant market driver.

3. Which Region accounted for the largest Genotyping Market share?
Ans- In 2023, North America accounted for XX % share of the global Genotyping market.

4. What makes North America a Lucrative Market for Genotyping Market?
Ans- North America held the biggest market share in 2023, primarily due to the rising acceptance of technologically advanced goods, and the presence of major pharmaceutical and biopharmaceutical businesses.

5. What are the top players operating in the Genotyping Market?
Ans- Illumina, Inc, Thermo Fisher Scientific Inc., Qiagen Inc., and F. Hoffmann-La Roche Ltd.